TearLab Corp  

(Public, NASDAQ:TEAR)   Watch this stock  
Find more results for TEAR
0.849
+0.199 (30.63%)
Real-time:   10:33AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.69 - 0.86
52 week 0.65 - 3.15
Open 0.71
Vol / Avg. 98,026.00/86,159.00
Mkt cap 25.18M
P/E     -
Div/yield     -
EPS -0.93
Shares 33.76M
Beta 3.34
Inst. own 36%
Mar 14, 2016
Q4 2015 TearLab Corp Earnings Release (Estimated) Add to calendar
Feb 1, 2016
Q4 2015 TearLab Corp Corporate Sales Release
Nov 19, 2015
TearLab Corp at Canaccord Genuity Medical Technology & Diagnostics Forum
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -121.96% -120.31%
Operating margin -114.08% -126.81%
EBITD margin - -111.91%
Return on average assets -113.30% -58.58%
Return on average equity -461.80% -72.16%
Employees 132 -
CDP Score - -

Address

Suite 200, 7360 Carroll Rd
SAN DIEGO, CA 92121
United States - Map
+1-858-4556006 (Phone)
+1-858-8120540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company is engaged in commercial manufacturing of the TearLab Osmolarity System. The Company's wholly owned subsidiary TearLab Research, Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (glucose), genes and proteins) at the point-of-care. The TearLab Osmolarity System measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). The TearLab Osmolarity System is an integrated testing system consisted of: the TearLab disposable, the TearLab Pen and the TearLab Reader.

Officers and directors

Elias Vamvakas Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Joseph Jensen President, Chief Executive Officer, Chief Operating Officer, Director
Age: 43
Bio & Compensation  - Reuters
Wes Brazell Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Raymond Kong Vice President - Sales
Bio & Compensation  - Reuters
Venkiteshwar Manoj Vice President of Medical Affairs
Age: 37
Bio & Compensation  - Reuters
Paul Smith Vice President - International Markets
Age: 37
Bio & Compensation  - Reuters
Duane Morrison Vice President - Business Development
Age: 51
Bio & Compensation  - Reuters
Anthony E. Altig Independent Director
Age: 59
Bio & Compensation  - Reuters
Thomas N. Davidson Jr. Independent Director
Age: 55
Bio & Compensation  - Reuters
Adrienne L. Graves Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters